The novel dual incretin analogue tirzepatide was shown to have superior effects compared to GLP-1R agonists in terms of weight loss, and tirzepatide was the first incretin analogue to show improved cardiovascular outcomes in a heart failure trial, however, so far only in patients with HFpEF [32]. This evidence concerns the gene GLP1R and heart failure.